Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Michael O'Riordan

December 14, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Conference News TCT 2017

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Yael L. Maxwell

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

News Daily News

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Yael L. Maxwell

October 20, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Daily News

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Shelley Wood

July 21, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Conference News EuroPCR 2017

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

Yael L. Maxwell

May 22, 2017

News Industry News

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

May 18, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

News Industry News

REVA to Expand FANTOM II Trial to More Complex Cases

March 24, 2017

Presentation CHIP Washington DC 2017

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

Presenter: Gregg W. Stone

March 21, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

CME

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2017

PCI Comparable to CABG in Left Main Coronary Disease: Meta-analysis

Live From Denver: TCT 2017, Day One

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Women, Minorities at Greater Risk for Non-Stent-Related Events After PCI

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

New Absorb BVS Meta-analysis Begs the Question: When to Stop Studying a First-Gen Device?

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

DISRUPT CAD: Lithoplasty May Modify Dense Calcium in Coronary Lesions Before Stenting

Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

The Left Main Debate: What Does it Mean for the Future of Intervention?

REVA to Expand FANTOM II Trial to More Complex Cases

A Brief Update of PCI for Left Main Disease: Perspectives After the EXCEL and NOBLE Trials

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

What’s Next for Left Main PCI?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content